LE WE PMID CA
Hepatitis C1136Hepatitis C

Aids

Alcohol

Antiviral agents

Boceprevir

CD81

Cryoglobulinemia

Disaster medicine

Glycyrrhizin

Hepatitis (BASKET)

Hepatitis B

Hepatitis C

Immunopsychiatry

Innate immunity

Insulin (resistance)

Interferon alpha (Therapeutic use)

Interferon lambda

Interleukin28B

Kidney (Diseases viral excl HIV)

Liver (Fibrosing cholestatic hepatitis)

Liver (Fibrosis)

Liver (Neoplasia)

Liver (Transplantation)

Neoplasia (Carcinogenesis)

Postexposition prophylaxis

Quasispecies

Ribavirin

RNA (MicroRNA)

Telaprevir

Tetanus

Ursodeoxycholic acid

Vasculitis (BASKET)

Virus (Immune reaction)

West nile virus

2006  
1
Diagnosis and treatment of chronic hepatitis C infection.
[16644828] BMJ 332(7548): 1013-7 (2006)
2005  
2
Extrahepatic manifestations of hepatitis C.
[16295816] South Med J 98(10): 1019-23 (2005)
2005  
3
Extrahepatic manifestations of hepatitis C.
[16295810] South Med J 98(10): 967-9 (2005)
2004  
4
Hepatitis C infection: a clinical review.
[15108830] South Med J 97(4): 364-73; quiz 374 (2004)
1997  
5
1994  
6
Serologic diagnosis of viral hepatitis.
[7517578] South Med J 87(7): 677-84 (1994)
2001  
7
Molecular virology of hepatitis C virus.
[11434427] Acta Med Okayama 55(3): 133-59 (2001)
2008  
8
Treatment of chronic hepatitis C virus infection - Dutch national guidelines.
[18663263] Neth J Med 66(7): 311-22 (2008)
2006  
9
Hepatitis C: changing genotype distribution with important implications for patient management.
[16609154] Neth J Med 64(4): 96-9 (2006)
2004  
10
The treatment of hepatitis C: history, presence and future.
[15209471] Neth J Med 62(3): 76-82 (2004)
2005  
11
Hepatitis C infection: a systemic disease with extrahepatic manifestations.
[16315439] Cleve Clin J Med 72(11): 1005-8, 1010-4, 1016 passim (2005)
2001  
12
Natural history of hepatitis C infection: a concise review.
[11697481] Yale J Biol Med 74(4): 229-37 (2001)
2007  
13
Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents.
[17907376] Antivir Chem Chemother 18(4): 169-89 (2007)
2005  
14
Host cell targets in HCV therapy: novel strategy or proven practice?
[15889531] Antivir Chem Chemother 16(2): 69-90 (2005)
2003  
15
Mechanisms of hepatitis C virus infection.
[14968935] Antivir Chem Chemother 14(6): 285-97 (2003)
2003  
16
Hepatitis C virus therapies: current treatments, targets and future perspectives.
[12790512] Antivir Chem Chemother 14(1): 1-21 (2003)
2001  
17
Treatment of chronic viral hepatitis.
[11771729] Antivir Chem Chemother 12(4): 201-12 (2001)
2000  
18
Novel approaches to the treatment of hepatitis C virus infection.
[10819433] Antivir Chem Chemother 11(2): 79-96 (2000)
1999  
19
Cell-based and animal models for hepatitis B and C viruses.
[10431609] Antivir Chem Chemother 10(3): 99-114 (1999)
2009  
20
Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.
[20032543] Antivir Ther 14(8): 1139-48 (2009)
2009  
21
Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.
[19430089] Antivir Ther 14(2): 143-54 (2009)
2008  
22
Future directions in therapy for chronic hepatitis C.
[18432161] Antivir Ther 13 Suppl 1(-): 31-6 (2008)
2008  
23
Optimizing outcomes in patients with hepatitis C virus genotype 2 or 3.
[18432159] Antivir Ther 13 Suppl 1(-): 17-22 (2008)
2008  
24
Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4.
[18432158] Antivir Ther 13 Suppl 1(-): 9-16 (2008)
2008  
25
Hepatitis C virus therapy to date.
[18432157] Antivir Ther 13 Suppl 1(-): 3-8 (2008)
2007  
26
Future treatment of chronic hepatitis C.
[18018759] Antivir Ther 12(7): 1015-25 (2007)
2006  
27
Optimizing treatment outcomes in chronic hepatitis C: management of non-response.
[17302365] Antivir Ther 11(8): 955-70 (2006)
2006  
28
Future therapies for hepatitis C.
[16856613] Antivir Ther 11(4): 397-408 (2006)
2006  
29
Oligonucleotide-based therapeutic options against hepatitis C virus infection.
[16759043] Antivir Ther 11(3): 273-87 (2006)
2005  
30
Chronic hepatitis C and genotyping: the clinical significance of determining HCV genotypes.
[15751759] Antivir Ther 10(1): 1-11 (2005)
2007  
31
Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
[17346498] Health Technol Assess 11(11): 1-205, iii (2007)
2008  
32
Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha.
[18776191] J Antimicrob Chemother 62(5): 860-5 (2008)
2010  
33
Antiviral therapy for hepatitis C: why are so few patients being treated?
[20460398] J Antimicrob Chemother 65(7): 1327-9 (2010)
2007  
34
Viral determinants of resistance to treatment in patients with hepatitis C.
[17223621] Clin Microbiol Rev 20(1): 23-38 (2007)
2000  
35
Clinical significance of hepatitis C virus genotypes.
[10755999] Clin Microbiol Rev 13(2): 223-35 (2000)
1994  
36
Hepatitis C: progress and problems.
[7834603] Clin Microbiol Rev 7(4): 505-32 (1994)
2002  
37
Laboratory assays for diagnosis and management of hepatitis C virus infection.
[12454127] J Clin Microbiol 40(12): 4407-12 (2002)
2009  
38
Hepatitis B and C virus-related carcinogenesis.
[19874379] Clin Microbiol Infect 15(11): 964-70 (2009)
2005  
39
2009  
40
Macrophages in hepatitis B and hepatitis C virus infections.
[18842723] J Virol 83(7): 2796-802 (2009)
2006  
41
Hepatitis C virus entry: potential receptors and their biological functions.
[16603507] J Gen Virol 87(Pt 5): 1075-84 (2006)
2004  
42
Hepatitis C virus NS5A: tales of a promiscuous protein.
[15302943] J Gen Virol 85(Pt 9): 2485-502 (2004)
2001  
43
Biogenesis of hepatitis C virus envelope glycoproteins.
[11602769] J Gen Virol 82(Pt 11): 2589-95 (2001)
2000  
44
Replication of hepatitis C virus.
[10859368] J Gen Virol 81(Pt 7): 1631-48 (2000)
1997  
45
Molecular virology of hepatitis C virus.
[9349458] J Gen Virol 78 ( Pt 10)(-): 2397-410 (1997)
2009  
46
Hepatitis C Virus entry: the early steps in the viral replication cycle.
[19643019] Virol J 6(-): 117 (2009)
2002  
47
Epidemiology and clinical aspects on hepatitis C.
[12195046] Jpn J Infect Dis 55(3): 69-77 (2002)
2008  
48
Early steps of the hepatitis C virus life cycle.
[18081727] Cell Microbiol 10(4): 821-7 (2008)
2007  
49
Management of chronic hepatitis C: consensus guidelines.
[17568824] Can J Gastroenterol 21 Suppl C(-): 25C-34C (2007)
2009  
50
Current and future treatment options for HCV.
[19502651] Ann Hepatol 8(2): 103-12 (2009)
2006  
51
Extrahepatic autoimmune manifestations of chronic hepatitis C virus infection.
[17060872] Ann Hepatol 5(3): 161-3 (2006)
2004  
52
Side effects of medical therapy for chronic hepatitis C.
[15118573] Ann Hepatol 3(1): 5-10 (2004)
2001  
53
Immunopathogenesis of hepatitis C virus infection.
[11903612] Immunol Cell Biol 79(6): 515-36 (2001)
2004  
54
Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis.
[15218054] J Leukoc Biol 76(4): 743-59 (2004)
2007  
55
Hepatitis C--new developments in the studies of the viral life cycle.
[17957276] Acta Biochim Pol 54(4): 703-15 (2007)
2005  
56
Existing and future therapeutic options for hepatitis C virus infection.
[15827606] Acta Biochim Pol 52(1): 57-70 (2005)
2003  
57
Regulatory mechanisms of viral hepatitis B and C.
[12734409] J Biosci 28(3): 311-21 (2003)
2003  
58
The hepatitis C virus persistence: how to evade the immune system?
[12734407] J Biosci 28(3): 287-304 (2003)
2003  
59
Variability or conservation of hepatitis C virus hypervariable region 1? Implications for immune responses.
[12734408] J Biosci 28(3): 305-10 (2003)
1999  
60
Hepatitis C-related hepatocellular carcinoma: prevalence around the world, factors interacting, and role of genotypes.
[10682256] Epidemiol Rev 21(2): 180-7 (1999)
2009  
61
Hepatitis C infection and chronic renal diseases.
[19129320] Clin J Am Soc Nephrol 4(1): 207-20 (2009)
2007  
62
Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.
[17451561] Aliment Pharmacol Ther 25(10): 1153-62 (2007)
2006  
63
Meta-analysis: anti-viral therapy of hepatitis C virus-related liver disease in renal transplant patients.
[17081162] Aliment Pharmacol Ther 24(10): 1413-22 (2006)
2006  
64
Review article: management of patients with chronic hepatitis C virus infection and "normal" alanine aminotransferase activity.
[17014573] Aliment Pharmacol Ther 24(8): 1133-49 (2006)
2006  
65
Review article: predicting response in hepatitis C virus therapy.
[16611264] Aliment Pharmacol Ther 23(8): 1043-54 (2006)
2005  
66
Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection.
[15771751] Aliment Pharmacol Ther 21(6): 653-62 (2005)
2005  
67
Dynamic decision analysis to determine optimal treatment duration in chronic hepatitis C.
[15740537] Aliment Pharmacol Ther 21(5): 539-47 (2005)
2004  
68
Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis.
[15606388] Aliment Pharmacol Ther 20(11-12): 1271-7 (2004)
2004  
69
Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.
[15521839] Aliment Pharmacol Ther 20(9): 931-8 (2004)
2004  
70
The management of side-effects during therapy for hepatitis C.
[15521838] Aliment Pharmacol Ther 20(9): 917-29 (2004)
2004  
71
Hepatitis C virus-related extra-hepatic disease--aetiopathogenesis and management.
[15233692] Aliment Pharmacol Ther 20(2): 129-41 (2004)
2003  
72
Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients.
[14653826] Aliment Pharmacol Ther 18(11-12): 1071-81 (2003)
2003  
73
Systematic review: peginterferon vs. standard interferon in the treatment of chronic hepatitis C.
[14510739] Aliment Pharmacol Ther 18(7): 661-70 (2003)
2003  
74
Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy.
[12969081] Aliment Pharmacol Ther 18(6): 549-58 (2003)
2001  
75
Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis.
[11328263] Aliment Pharmacol Ther 15(5): 689-98 (2001)
1998  
76
Review article: glycyrrhizin as a potential treatment for chronic hepatitis C.
[9570253] Aliment Pharmacol Ther 12(3): 199-205 (1998)
2009  
77
Review article: investigational agents for chronic hepatitis C.
[19183149] Aliment Pharmacol Ther 29(7): 689-705 (2009)
2008  
78
Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.
[18549461] Aliment Pharmacol Ther 28(4): 397-404 (2008)
2008  
79
Review article: novel therapeutic options for chronic hepatitis C.
[18284651] Aliment Pharmacol Ther 27(10): 866-84 (2008)
2003  
80
The roles of hepatitis C virus proteins in modulation of cellular functions: a novel action mechanism of the HCV core protein on gene regulation by nuclear hormone receptors.
[14611668] Cancer Sci 94(11): 937-43 (2003)
2003  
81
Oral diseases possibly associated with hepatitis C virus.
[12764074] Crit Rev Oral Biol Med 14(2): 115-27 (2003)
2004  
82
2004  
83
2008  
84
1996  
85
2006  
86
Perinatal hepatitis C virus infection: diagnosis and management.
[16923861] Arch Dis Child 91(9): 781-5 (2006)
2007  
87
The kidney transplant recipient with hepatitis C infection: pre- and posttransplantation treatment.
[17699464] Clin J Am Soc Nephrol 2(3): 563-75 (2007)
2006  
88
Altered monoaminergic transporter binding in hepatitis C related cerebral dysfunction: a neuroimmunologial condition?
[17047105] Gut 55(11): 1535-7 (2006)
2006  
89
Treating viral hepatitis C: efficacy, side effects, and complications.
[16905701] Gut 55(9): 1350-9 (2006)
2006  
90
Acute hepatitis C virus infection: a neglected disease?
[16849345] Gut 55(8): 1075-7 (2006)
2001  
91
Clinical guidelines on the management of hepatitis C.
[11413125] Gut 49 Suppl 1(-): I1-21 (2001)
1998  
92
French consensus conference on hepatitis C: screening and treatment.
[9691933] Gut 42(6): 892-8 (1998)
2008  
93
Therapy of hepatitis C virus-associated glomerulonephritis: current approaches.
[19034865] J Nephrol 21(6): 813-25 (2008)
2000  
94
The natural history of hepatitis C virus infection: host, viral, and environmental factors.
[10904508] JAMA 284(4): 450-6 (2000)
1998  
95
Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis.
[9690235] Kidney Int 54(2): 650-71 (1998)
2007  
96
Hepatitis C virus: from entry to renal injury--facts and potentials.
[17478492] Nephrol Dial Transplant 22(7): 1840-8 (2007)
2000  
97
Treatment of hepatitis C virus infection in dialysis patients.
[11261704] Nephrol Dial Transplant 15 Suppl 8(-): 46-8 (2000)
2000  
98
Hepatitis C virus-induced liver disease in dialysis patients.
[11261703] Nephrol Dial Transplant 15 Suppl 8(-): 42-5 (2000)
2000  
99
Treatment of glomerulonephritides associated with hepatitis C virus infection.
[11261701] Nephrol Dial Transplant 15 Suppl 8(-): 34-8 (2000)
2000  
100
Glomerular disease associated with hepatitis C virus infection in native kidneys.
[11261700] Nephrol Dial Transplant 15 Suppl 8(-): 28-33 (2000)
2000  
101
2000  
102
The natural history of hepatitis C virus infection.
[11261697] Nephrol Dial Transplant 15 Suppl 8(-): 19-23 (2000)
2000  
103
Diagnostic tests for hepatitis C virus infection.
[11261696] Nephrol Dial Transplant 15 Suppl 8(-): 15-8 (2000)
2005  
104
Management of chronic hepatitis C.
[15937203] Postgrad Med J 81(956): 376-82 (2005)
2007  
105
Hepatitis C virus infection, cryoglobulinaemia, and beyond.
[17317717] Rheumatology (Oxford) 46(4): 572-8 (2007)
2003  
106
Therapeutic management of extrahepatic manifestations in patients with chronic hepatitis C virus infection.
[12730523] Rheumatology (Oxford) 42(7): 818-28 (2003)
2001  
107
1991  
108
Hepatitis C virus. A review.
[1656611] West J Med 155(2): 164-8 (1991)
2007  
109
Hepatitis C virus-related lymphoproliferative disorders: an overview.
[17552031] World J Gastroenterol 13(17): 2467-78 (2007)
2007  
110
Hepatitis C virus: virology, diagnosis and management of antiviral therapy.
[17552030] World J Gastroenterol 13(17): 2461-6 (2007)
2007  
111
2008  
112
Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection.
[18972443] Hepatology 48(5): 1700-12 (2008)
2008  
113
Treatment of chronic hepatitis C in hemodialysis patients.
[18972442] Hepatology 48(5): 1690-9 (2008)
2008  
114
Hepatitis C genotype 4: What we know and what we don't yet know.
[18240152] Hepatology 47(4): 1371-83 (2008)
2006  
115
Hepatitis C virus entry: molecular biology and clinical implications.
[16941688] Hepatology 44(3): 527-35 (2006)
2006  
116
Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences.
[16799966] Hepatology 44(1): 15-22 (2006)
2005  
117
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes.
[16149085] Hepatology 42(4): 962-73 (2005)
2004  
118
Diagnosis, management, and treatment of hepatitis C.
[15057920] Hepatology 39(4): 1147-71 (2004)
2004  
119
Structural biology of hepatitis C virus.
[14752815] Hepatology 39(1): 5-19 (2004)
2003  
120
Kinetics of the immune response during HBV and HCV infection.
[12829979] Hepatology 38(1): 4-13 (2003)
2002  
121
Side effects of therapy of hepatitis C and their management.
[12407599] Hepatology 36(5 Suppl 1): S237-44 (2002)
2002  
122
Role of liver biopsy in management of chronic hepatitis C: a systematic review.
[12407590] Hepatology 36(5 Suppl 1): S161-72 (2002)
2002  
123
The role of liver biopsy in chronic hepatitis C.
[12407589] Hepatology 36(5 Suppl 1): S152-60 (2002)
2002  
124
Monitoring of viral levels during therapy of hepatitis C.
[12407588] Hepatology 36(5 Suppl 1): S145-51 (2002)
2002  
125
Treatment of chronic hepatitis C: a systematic review.
[12407587] Hepatology 36(5 Suppl 1): S135-44 (2002)
2002  
126
Use and interpretation of virological tests for hepatitis C.
[12407578] Hepatology 36(5 Suppl 1): S65-73 (2002)
2002  
127
Natural history of chronic hepatitis C.
[12407575] Hepatology 36(5 Suppl 1): S35-46 (2002)
2001  
128
2000  
129
Natural history of hepatitis C: its impact on clinical management.
[10733560] Hepatology 31(4): 1014-8 (2000)
1997  
130
1997  
131
The molecular virology of hepatitis C.
[9185778] Hepatology 25(6): 1527-38 (1997)
1994  
132
Renal manifestations of hepatitis C virus infection.
[7853784] Kidney Int 46(5): 1255-63 (1994)
2002  
133
The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis.
[12065893] J Biomed Sci 9(3): 187-97 (2002)
2004  
134
Molecular biology and clinical implication of hepatitis C virus.
[15107931] Braz J Med Biol Res 37(5): 691-5 (2004)
2010  
135
Hepatitis C virus: molecular biology & current therapeutic options.
[20167971] Indian J Med Res 131(-): 17-34 (2010)
2006  
136
Hepatitis C: a review for primary care physicians.
[16505462] CMAJ 174(5): 649-59 (2006)
2011  
137
Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?
[21677327] Ann Hepatol 10(3): 260-9 (2011)
2011  
138
Treatment issues surrounding hepatitis C in renal transplantation: a review.
[21301003] Ann Hepatol 10(1): 5-14 (2011)
2004  
139
Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat.
[15083850] Ann Fam Med 2(2): 116-24 (2004)
2003  
140
Review article: indicators and predictors of response to anti-viral therapy in chronic hepatitis C.
[12641509] Aliment Pharmacol Ther 17(5): 611-21 (2003)
2007  
141
Viral infections and the kidney: HIV, hepatitis B, and hepatitis C.
[17506240] Cleve Clin J Med 74(5): 353-60 (2007)
2010  
142
Post-liver transplant cholestatic hepatitis C: a systematic review of clinical and pathological findings and application of consensus criteria.
[21031537] Liver Transpl 16(11): 1228-35 (2010)
2003  
143
The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients.
[14586892] Liver Transpl 9(11): S28-34 (2003)
2003  
144
Hepatitis C pathogenesis: mechanisms of viral clearance and liver injury.
[14586893] Liver Transpl 9(11): S35-43 (2003)
2003  
145
Hepatitis C virus quasispecies: misunderstood and mistreated?
[14526399] Liver Transpl 9(10): 1048-52 (2003)
2008  
146
How accurately and how early can we predict rapid fibrosis progression in hepatitis C virus-infected patients after liver transplantation?
[18756466] Liver Transpl 14(9): 1237-9 (2008)
2008  
147
The natural history of recurrent hepatitis C and what influences this.
[18825724] Liver Transpl 14 Suppl 2(-): S36-44 (2008)
2008  
148
Extrahepatic hepatitis C virus after transplantation: diabetes and renal dysfunction.
[18825714] Liver Transpl 14 Suppl 2(-): S51-7 (2008)
2008  
149
Hepatitis C therapy before and after liver transplantation.
[18825697] Liver Transpl 14 Suppl 2(-): S58-66 (2008)
2008  
150
Identifying activated hepatic stellate cells in chronic and posttransplant recurrent hepatitis C.
[18508367] Liver Transpl 14(6): 756-8 (2008)
2011  
151
Neuropsychological alterations in hepatitis C infection: the role of inflammation.
[21876628] World J Gastroenterol 17(29): 3369-74 (2011)
2011  
152
Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry.
[21734774] World J Gastroenterol 17(22): 2683-90 (2011)
2011  
153
Animal models for studying hepatitis C and alcohol effects on liver.
[21633656] World J Gastroenterol 17(20): 2515-9 (2011)
2011  
154
Influence of occult hepatitis B virus infection in chronic hepatitis C outcomes.
[21472121] World J Gastroenterol 17(12): 1558-62 (2011)
2011  
155
Peginterferon and ribavirin treatment for hepatitis C virus infection.
[21274371] World J Gastroenterol 17(4): 419-32 (2011)
2010  
156
Importance of hepatitis C virus-associated insulin resistance: therapeutic strategies for insulin sensitization.
[20419831] World J Gastroenterol 16(16): 1943-52 (2010)
2007  
157
Sequence diversity of hepatitis C virus: implications for immune control and therapy.
[17828811] World J Gastroenterol 13(36): 4808-17 (2007)
2007  
158
Specifically targeted antiviral therapy for hepatitis C virus.
[17963291] World J Gastroenterol 13(43): 5673-81 (2007)
2007  
159
Treatment of hepatitis C virus infection.
[17461488] World J Gastroenterol 13(13): 1897-905 (2007)
2009  
160
Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review.
[19673011] World J Gastroenterol 15(30): 3713-24 (2009)
2009  
161
New therapies for hepatitis C virus infection.
[19123867] Clin Infect Dis 48(3): 313-20 (2009)
2009  
162
Hepatitis C treatment for injection drug users: a review of the available evidence.
[19589081] Clin Infect Dis 49(4): 561-73 (2009)
2008  
163
Rapid virologic response: a new milestone in the management of chronic hepatitis C.
[18171217] Clin Infect Dis 46(1): 78-84 (2008)
2010  
164
A new insight into hepatitis C vaccine development.
[20625493] J Biomed Biotechnol 2010(-): 548280 (2010)
2003  
165
2010  
166
Hepatitis C virus: assembly and release of virus particles.
[20457608] J Biol Chem 285(30): 22733-9 (2010)
2008  
167
2009  
168
Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.
[19587449] J Clin Invest 119(7): 1745-54 (2009)
2010  
169
Targeting viral infection by microRNA inhibition.
[20122293] Genome Biol 11(1): 201 (2010)
2008  
170
Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis.
[18605975] Biochemistry (Mosc) 73(5): 504-13 (2008)
2008  
171
Hepatitis C virus genotypes: clinical relevance and therapeutic implications.
[18419050] Chang Gung Med J 31(1): 16-25 (2008)
2008  
172
Practical consequences of hepatitis C virus quasispecies for target-specific antivirals.
[18637751] J Infect Dis 198(6): 797-9 (2008)
2011  
173
Impact of the autophagy machinery on hepatitis C virus infection.
[21994783] Viruses 3(8): 1342-57 (2011)
2011  
174
Recombination in hepatitis C virus.
[22069526] Viruses 3(10): 2006-24 (2011)
2010  
175
Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.
[21994615] Viruses 2(10): 2169-95 (2010)
2010  
176
The Future of HCV Therapy: NS4B as an Antiviral Target.
[21157574] Viruses 2(11): 2481-92 (2010)
2010  
177
Recent advances in hepatitis C virus cell entry.
[21994653] Viruses 2(3): 692-709 (2010)
2010  
178
Lipid metabolism and HCV infection.
[21994676] Viruses 2(5): 1195-217 (2010)
2011  
179
Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
[21473834] Health Technol Assess 15(17): i-xii, 1-210 (2011)
2004  
180
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
[15461877] Health Technol Assess 8(39): iii-iv, 1-125 (2004)
2010  
181
Interferon therapy of hepatitis C: molecular insights into success and failure.
[19950038] Swiss Med Wkly 140(1-2): 3-11 (2010)
2009  
182
Insulin resistance in chronic hepatitis C: mechanisms and clinical relevance.
[20047129] Swiss Med Wkly 139(47-48): 678-84 (2009)
2009  
183
The role of iron in the pathophysiology and treatment of chronic hepatitis C.
[20011735] Can J Gastroenterol 23(12): 822-8 (2009)
2009  
184
Perspectives on the management of chronic hepatitis B and C.
[19344237] Expert Rev Anti Infect Ther 7(3): 243-7 (2009)
2009  
185
Ribavirin in chronic hepatitis C: past and future.
[19344238] Expert Rev Anti Infect Ther 7(3): 249-53 (2009)
2010  
186
Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors.
[20688770] J Antimicrob Chemother 65(10): 2063-9 (2010)
2010  
187
Moving beyond interferon alfa: investigational drugs for hepatitis C virus infection.
[21107012] Top HIV Med 18(4): 132-6 (2010)
2011  
188
Treatment of acute hepatitis C virus infection in HIV+ patients: Dutch recommendations for management.
[21325703] Neth J Med 69(1): 43-9 (2011)
2004  
189
Virus-induced systemic vasculitides: new therapeutic approaches.
[15559368] Clin Dev Immunol 11(3-4): 227-31 (2004)
2007  
190
2007  
191
Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach.
[17486049] Mod Pathol 20 Suppl 1(-): S3-14 (2007)
2005  
192
Treatment of hepatitis C virus-related systemic vasculitis.
[16265682] J Rheumatol 32(11): 2078-82 (2005)
2004  
193
Antiviral therapy of recurrent hepatitis C in liver transplantation.
[15053735] Rev Esp Enferm Dig 96(3): 201-14 (2004)
2005  
194
Hepatitis C: are there any options for non-responders?
[16004521] Rev Esp Enferm Dig 97(5): 299-305 (2005)
2007  
195
Innate immune evasion by hepatitis C virus and West Nile virus.
[17702639] Cytokine Growth Factor Rev 18(5-6): 535-44 (2007)
2008  
196
2004  
197
Diagnosis and treatment of hepatitis C.
[15121811] J R Soc Med 97(5): 223-5 (2004)
2010  
198
Outcome of antiviral treatment in patients with chronic genotype 1 HCV hepatitis. A retrospective study in 507 patients.
[20922189] J Gastrointestin Liver Dis 19(3): 261-4 (2010)
2011  
199
Human cell types important for hepatitis C virus replication in vivo and in vitro: old assertions and current evidence.
[21745397] Virol J 8(-): 346 (2011)
2011  
200
siRNAs: potential therapeutic agents against hepatitis C virus.
[21645341] Virol J 8(-): 276 (2011)
2011  
201
An overview of HCV molecular biology, replication and immune responses.
[21477382] Virol J 8(-): 161 (2011)
2011  
202
Hepatitis C virus infection: molecular pathways to insulin resistance.
[22008087] Virol J 8(-): 474 (2011)
2010  
203
Hepatitis C treatment: current and future perspectives.
[21040548] Virol J 7(-): 296 (2010)
2010  
204
Hepatitis C virus hijacks host lipid metabolism.
[19854061] Trends Endocrinol Metab 21(1): 33-40 (2010)
2011  
205
Interferon lambdas: the next cytokine storm.
[21303914] Gut 60(9): 1284-93 (2011)
2007  
206
Ursodeoxycholic acid in chronic hepatitis C.
[17998321] Gut 56(12): 1652-3 (2007)
2009  
207
Gumming up the works: DNA polymers as HCV entry inhibitors.
[19563837] Gastroenterology 137(2): 427-30 (2009)
2010  
208
New direct-acting antivirals in the development for hepatitis C virus infection.
[21180601] Therap Adv Gastroenterol 3(3): 191-202 (2010)
2005  
209
Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials.
[16246984] Arch Intern Med 165(19): 2206-12 (2005)
2009  
210
Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C.
[20428640] Braz J Infect Dis 13(5): 375-82 (2009)
2008  
211
Fibrosing cholestatic hepatitis: clinicopathologic spectrum, diagnosis and pathogenesis.
[18787628] Int J Clin Exp Pathol 1(5): 396-402 (2008)
2011  
212
Clinical implications of chemokines in acute and chronic hepatitis C virus infection.
[22028149] Yonsei Med J 52(6): 871-8 (2011)
2003  
213
Epidemiology of viruses causing chronic hepatitis among populations from the Amazon Basin and related ecosystems.
[14999325] Cad Saude Publica 19(6): 1583-91 (2003)
2011  
214
Management of HCV infection in chronic kidney disease.
[21407274] Nefrologia 31(3): 260-7 (2011)
2007  
215
The way forward in HCV treatment--finding the right path.
[18049473] Nat Rev Drug Discov 6(12): 991-1000 (2007)
2007  
216
The design of drugs for HIV and HCV.
[18049474] Nat Rev Drug Discov 6(12): 1001-18 (2007)
2009  
217
Hepatitis C virus-induced cryoglobulinemia.
[19606079] Kidney Int 76(8): 818-24 (2009)
2011  
218
Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
[22050393] J Manag Care Pharm 17(9): 685-94 (2011)
2009  
219
Caspase inhibitors for the treatment of hepatitis C.
[19628162] Clin Liver Dis 13(3): 467-75 (2009)
2008  
220
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.
[18161743] Hepatology 47(1): 306-20 (2008)
2008  
221
Acute hepatitis C virus infection: a chronic problem.
[18161707] Hepatology 47(1): 321-31 (2008)
2008  
222
2008  
223
Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection.
[18215981] HIV Clin Trials 9(1): 43-51 (2008)
2009  
224
Treatment failure in hepatitis C: mechanisms of non-response.
[19070928] J Hepatol 50(2): 412-20 (2009)
2008  
225
Hepatitis C: a clinical review.
[18173443] Oral Dis 14(1): 10-4 (2008)
2009  
226
Hepatitis C in the elderly: epidemiology, natural history, and treatment.
[19084480] Clin Gastroenterol Hepatol 7(2): 128-34; quiz 124 (2009)
2010  
227
Cryoglobulinemia in elderly patients with HCV-related chronic hepatitis.
[21577299] World J Gastrointest Pharmacol Ther 1(2): 72-4 (2010)
2010  
228
Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin.
[20633102] Liver Int 30(9): 1259-69 (2010)
2007  
229
Managing chronic hepatitis C in the difficult-to-treat patient.
[18036096] Liver Int 27(10): 1297-310 (2007)
2009  
230
Expert opinion on the treatment of patients with chronic hepatitis C.
[18761607] J Viral Hepat 16(2): 75-90 (2009)
2010  
231
New treatments for chronic hepatitis C.
[20924208] Korean J Hepatol 16(3): 263-77 (2010)
2011  
232
In-vitro model systems to study Hepatitis C Virus.
[21466709] Genet Vaccines Ther 9(-): 7 (2011)
2011  
233
Antiviral drugs against hepatitis C virus.
[21699699] Genet Vaccines Ther 9(-): 11 (2011)
2008  
234
Recommendations for postexposure interventions to prevent infection with hepatitis B virus, hepatitis C virus, or human immunodeficiency virus, and tetanus in persons wounded during bombings and other mass-casualty events--United States, 2008: recommendations of the Centers for Disease Control and Prevention (CDC).
[18668022] MMWR Recomm Rep 57(RR-6): 1-21; quiz CE1-4 (2008)
2008  
235
2007  
236
Studying hepatitis C virus: making the best of a bad virus.
[17522203] J Virol 81(17): 8853-67 (2007)
2009  
237
Hepatitis C virus cell entry: role of lipoproteins and cellular receptors.
[19264629] J Gen Virol 90(Pt 5): 1055-70 (2009)
2010  
238
Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus.
[20645875] J Interferon Cytokine Res 30(8): 585-90 (2010)
2011  
239
Current treatment of choice for chronic hepatitis C infection.
[21694905] Infect Drug Resist 4(-): 11-8 (2011)
2011  
240
An experimental mouse model for hepatitis C virus.
[21512264] Exp Anim 60(2): 93-100 (2011)
2010  
241
IL28B and the control of hepatitis C virus infection.
[20950615] Gastroenterology 139(6): 1865-76 (2010)
2011  
242
Virological tools to diagnose and monitor hepatitis C virus infection.
[21054664] Clin Microbiol Infect 17(2): 116-21 (2011)
2011  
243
Experimental models to study the immunobiology of hepatitis C virus.
[21148278] J Gen Virol 92(Pt 3): 477-93 (2011)
2010  
244
The Need for New Anti-Hepatitis C Virus Therapeutic Strategies: Targeting the cellular micro-ribonucleic acids?
[21509250] Sultan Qaboos Univ Med J 10(3): 312-7 (2010)
PMC   
245
Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.
[23439301] J Pediatr Gastroenterol Nutr 56(3):304-10 (2013)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


  • Hepatitis-C-Virus (HCV)-Infektion; Prophylaxe, Diagnostik und Therapie
  • Virale Meningoenzephalitis


  • Search PubMed and many other databases on the combined search terms

    GG: hcv
    GG: hepatitis c

  • Hepatitis C

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia